Literature DB >> 28057740

Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia.

Miriam Frech1, Lutz B Jehn1, Kathleen Stabla1, Stephan Mielke2, Björn Steffen3, Hermann Einsele2, Stephan K Metzelder1, Andreas Neubauer4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28057740      PMCID： PMC5395131          DOI： 10.3324/haematol.2016.160531

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  A new partner gene fused to ABL1 in a t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.

Authors:  E De Braekeleer; N Douet-Guilbert; M-J Le Bris; C Berthou; F Morel; M De Braekeleer
Journal:  Leukemia       Date:  2007-05-31       Impact factor: 11.528

2.  Advanced Philadelphia chromosome positive acute lymphoblastic leukemia patients relapsed after treatment with tyrosine-kinase inhibitors: successful response to clofarabine and cyclophosphamide.

Authors:  Antonella Vitale; Sara Grammatico; Saveria Capria; Carina Fiocchi; Robin Foà; Giovanna Meloni
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

3.  A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).

Authors:  Satu Mustjoki; Sari Hernesniemi; Auvo Rauhala; Marketta Kähkönen; Anders Almqvist; Tuija Lundán; Kimmo Porkka
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

4.  The t(1;9)(p34;q34) fusing ABL1 with SFPQ, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias.

Authors:  Francois P Duhoux; Nathalie Auger; Sigrid De Wilde; Sebastian Wittnebel; Geneviève Ameye; Khadija Bahloula; Catherine Van den Berg; Jeanne-Marie Libouton; Pascale Saussoy; Francis H Grand; Jean-Baptiste Demoulin; Hélène A Poirel
Journal:  Leuk Res       Date:  2011-03-09       Impact factor: 3.156

Review 5.  ABL1 fusion genes in hematological malignancies: a review.

Authors:  Etienne De Braekeleer; Nathalie Douet-Guilbert; David Rowe; Nick Bown; Frédéric Morel; Christian Berthou; Claude Férec; Marc De Braekeleer
Journal:  Eur J Haematol       Date:  2011-03-23       Impact factor: 2.997

6.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

7.  Management of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  O G Ottmann
Journal:  Leuk Suppl       Date:  2012-08-09

8.  The phosphorylation of CapZ-interacting protein (CapZIP) by stress-activated protein kinases triggers its dissociation from CapZ.

Authors:  Claire E Eyers; Helen McNeill; Axel Knebel; Nick Morrice; Simon J C Arthur; Ana Cuenda; Philip Cohen
Journal:  Biochem J       Date:  2005-07-01       Impact factor: 3.857

9.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.

Authors:  Y Collette; T Prébet; A Goubard; J Adélaïde; R Castellano; N Carbuccia; S Garnier; A Guille; C Arnoulet; A Charbonier; M J Mozziconacci; D Birnbaum; M Chaffanet; N Vey
Journal:  Blood Cancer J       Date:  2015-03-13       Impact factor: 11.037
View more
  5 in total

Review 1.  New Approaches to Treating Challenging Subtypes of ALL in AYA Patients.

Authors:  Kevin Prescott; Michael Jacobs; Wendy Stock; Joseph Wynne
Journal:  Curr Hematol Malig Rep       Date:  2020-12       Impact factor: 3.952

2.  Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing.

Authors:  Elisabeth K M Mack; André Marquardt; Danny Langer; Petra Ross; Alfred Ultsch; Michael G Kiehl; Hildegard I D Mack; Torsten Haferlach; Andreas Neubauer; Cornelia Brendel
Journal:  Haematologica       Date:  2018-09-06       Impact factor: 9.941

3.  A novel methylation signature predicts radiotherapy sensitivity in glioma.

Authors:  Yuemei Feng; Guanzhang Li; Zhongfang Shi; Xu Yan; Zhiliang Wang; Haoyu Jiang; Ye Chen; Renpeng Li; You Zhai; Yuanhao Chang; Wei Zhang; Fang Yuan
Journal:  Sci Rep       Date:  2020-11-23       Impact factor: 4.379

4.  Identification of IL10RA by Weighted Correlation Network Analysis and in vitro Validation of Its Association With Prognosis of Metastatic Melanoma.

Authors:  Si Cheng; Zhe Li; Wenhao Zhang; Zhiqiang Sun; Zhigang Fan; Judong Luo; Hui Liu
Journal:  Front Cell Dev Biol       Date:  2021-01-08

Review 5.  How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia.

Authors:  Avraham Frisch; Yishai Ofran
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.